Traws Pharma (TRAW) said Monday it entered agreements to raise up to $72.6 million through an equity offering.
An initial tranche of $20 million will involve the sale of around 3.9 million shares of common stock and pre-paid warrants, with an additional $52.6 million contingent on the exercise of non-prepaid warrants tied to upcoming bird flu data milestones in early and mid-2025, Traws Pharma said.
Closing is expected around Tuesday, the company said.
Traws Pharma shares plunged more than 37% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。